Physician profile
Mayra Munoz
NPI 1730869827
$2,071.94
in general payments reported to CMS, 2019-2025
23 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $206 · 2024: $1,084 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $547.17 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $250.39 | 2023-2025 | |
| Novo Nordisk INC | $164.93 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $131.05 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $116.54 | 2024-2025 | |
| Amgen INC. | $113.63 | 2023-2024 | Otezla, Repatha, Krystexxa |
| Astellas Pharma US INC | $109.99 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $104.04 | 2023-2024 | Accrufer |
| Lilly USA, LLC | $82.56 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $60.17 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $50.03 | 2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $45.85 | 2024-2025 | Ecc Solutions, (Ck7) Extended Holter |
| Boston Scientific Corporation | $45.44 | 2023-2025 | Bodyguardian |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.43 | 2024-2025 | Xifaxan |
| Eisai INC. | $32.90 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $31.54 | 2025 | Neurostar Tms Therapy System |
| Biogen, INC. | $25.67 | 2024 | Spinraza |
| Ars Pharmaceuticals Operations, INC. | $24.07 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $22.58 | 2025 | Dojolvi |
| Baxter Healthcare | $22.52 | 2025 | Hillrom - Monarch Airway Clearance System |
| Medicomp INC | $21.91 | 2024 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $16.15 | 2025 | Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayra Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.